Mary Lynne Hedley, Ph.D. has been appointed executive vice president of operations and chief scientific officer of Abraxis BioScience. Dr. Hedley most recently served as executive vice president of Eisai Corp. of North America following Eisai’s acquisition of MGI Pharma, where she had served as executive vice president and chief scientific officer since 2005. She joined MGI in 2004 as senior vice president and general manager. Previously, Dr. Hedley co-founded Zycos, Inc., a biotechnology company, and held roles of progressively greater responsibility ultimately leading to her serving as the company’s president and chief executive officer.

“Mary Lynne is an exemplary leader with a strong track record of driving the growth of biotechnology companies,” said Lonnie Moulder, president and chief executive officer of Abraxis. “Her general management and R&D leadership experience, coupled with a deep scientific background, make her an ideal addition to our executive team. We are very pleased to have this experienced executive join Abraxis as we advance our mission to enhance the lives of cancer patients throughout the world.”